Free Trial
NASDAQ:ITRM

Iterum Therapeutics Q2 2025 Earnings Report

Iterum Therapeutics logo
$0.71 -0.02 (-2.49%)
Closing price 08/4/2025 04:00 PM Eastern
Extended Trading
$0.78 +0.07 (+9.27%)
As of 05:50 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Upcoming Event
Earnings Conference Call
Iterum Therapeutics Q2 2025
00:00 / 00:00
Live Transcript
Follow Audio

Iterum Therapeutics EPS Results

Actual EPS
N/A
Consensus EPS
-$0.13
Beat/Miss
N/A
One Year Ago EPS
N/A

Iterum Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Iterum Therapeutics Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Tuesday, August 5, 2025
Conference Call Time
8:30AM ET

Conference Call Resources

Iterum Therapeutics Earnings Headlines

Iterum Therapeutics Q2 Earnings Preview
Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks.
Insights Ahead: Iterum Therapeutics's Quarterly Earnings
Iterum Therapeutics plc (ITRM) - Yahoo Finance
See More Iterum Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Iterum Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Iterum Therapeutics and other key companies, straight to your email.

About Iterum Therapeutics

Iterum Therapeutics (NASDAQ:ITRM), a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.

View Iterum Therapeutics Profile

More Earnings Resources from MarketBeat